ArticleTranslational cancer research2026
A nomogram integrating multidimensional lymph node indicators with clinicopathological factors predicts overall survival in non-metastatic gastric cancer patients after radical gastrectomy.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-metastatic gastric cancer patients undergoing radical gastrectomy still show substantial prognostic heterogeneity. The conventional American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system, particularly N stage, may be affected by variations in examined lymph node (ELN), resulting in stage migration. We aimed to evaluate the efficacy of a multifactor model incorporating the log odds of positive lymph nodes (LODDS), ELN, and N stage in survival prediction for patients with non-metastatic gastric cancer undergoing radical gastrectomy, and to construct an accurate prognostic prediction model. Methods: Clinicopathological data of patients with non-metastatic gastric cancer who underwent radical gastrectomy between 2010 and 2019 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Independent risk factors for overall survival (OS) were determined using univariate Cox regression, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox analysis. A nomogram was subsequently established according to these factors. The prognostic performance and clinical utility of the model were evaluated in the training, validation, and overall cohorts using the concordance index (C-index), receiver operating characteristic (ROC) curves, Akaike information criterion (AIC), calibration curves, net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). Patients were stratified into different risk groups based on the total nomogram scores, and the discriminatory ability was validated using Kaplan-Meier survival curves. Results: Multivariate Cox analysis revealed that age, race, tumor size, T stage, N stage, ELN, LODDS, and chemotherapy status were independent prognostic factors. The areas under the curves (AUCs) of the nomogram for predicting 1-, 3-, and 5-year OS in the training, validation, and overall cohorts all exceeded 0.76, outperforming the AJCC TNM staging system (all AUCs <0.72). Calibration curves demonstrated close agreement between predicted and observed survival outcomes. DCA, NRI, and IDI analyses further confirmed that the nomogram provided superior clinical net benefit and improved discrimination compared with the TNM staging system. The risk stratification (low-, middle-, and high-risk groups) based on the model scores significantly distinguished different survival outcomes (P<0.001). Conclusions: The nomogram integrating multidimensional factors including LODDS, ELN, and traditional TNM staging is a reliable prognostic tool for patients with non-metastatic gastric cancer after radical gastrectomy. Compared with the conventional TNM staging system, this model exhibits superior predictive accuracy and clinical applicability, assisting clinicians in individualized prognostic assessment and adjuvant treatment decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.